» Articles » PMID: 33919503

Effects of Low-Carbohydrate Versus Mediterranean Diets on Weight Loss, Glucose Metabolism, Insulin Kinetics and β-Cell Function in Morbidly Obese Individuals

Overview
Journal Nutrients
Date 2021 Apr 30
PMID 33919503
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Low-calorie Mediterranean-style or low-carbohydrate dietary regimens are widely used nutritional strategies against obesity and associated metabolic diseases, including type 2 diabetes. The aim of this study was to compare the effectiveness of a balanced Mediterranean diet with a low-carbohydrate diet on weight loss and glucose homeostasis in morbidly obese individuals at high risk to develop diabetes. Insulin secretion, insulin clearance, and different β-cell function components were estimated by modeling plasma glucose, insulin and C-peptide profiles during 75-g oral glucose tolerance tests (OGTTs) performed at baseline and after 4 weeks of each dietary intervention. The average weight loss was 5%, being 58% greater in the low-carbohydrate-group than Mediterranean-group. Fasting plasma glucose and glucose tolerance were not affected by the diets. The two dietary regimens proved similarly effective in improving insulin resistance and fasting hyperinsulinemia, while enhancing endogenous insulin clearance and β-cell glucose sensitivity. In summary, we demonstrated that a low-carbohydrate diet is a successful short-term approach for weight loss in morbidly obese patients and a feasible alternative to the Mediterranean diet for its glucometabolic benefits, including improvements in insulin resistance, insulin clearance and β-cell function. Further studies are needed to compare the long-term efficacy and safety of the two diets.

Citing Articles

Determinants of adherence to the Mediterranean diet among individuals with type 2 diabetes mellitus living in Mediterranean countries: a systematic review.

Ayoub J, Haidar S, Blaak E, De Vries N Front Nutr. 2025; 12:1523995.

PMID: 39963667 PMC: 11830624. DOI: 10.3389/fnut.2025.1523995.


Targeting GABA signaling in type 1 diabetes and its complications- an update on the state of the art.

Laszczych D, Czernicka A, Laszczych K Pharmacol Rep. 2025; .

PMID: 39833509 DOI: 10.1007/s43440-025-00697-7.


Postprandial hypoglycaemia after gastric bypass in type 2 diabetes: pathophysiological mechanisms and clinical implications.

Trico D, Sacchetta L, Rebelos E, Cimbalo N, Chiriaco M, Moriconi D Diabetologia. 2024; 68(2):444-459.

PMID: 39611961 DOI: 10.1007/s00125-024-06312-3.


Insights in Nutrition to Optimize Type 1 Diabetes Therapy.

Cadario F Nutrients. 2024; 16(21).

PMID: 39519472 PMC: 11547730. DOI: 10.3390/nu16213639.


Exogenous Nucleotides Ameliorate Insulin Resistance Induced by Palmitic Acid in HepG2 Cells through the IRS-1/AKT/FOXO1 Pathways.

Song L, Li Y, Xu M Nutrients. 2024; 16(12).

PMID: 38931156 PMC: 11206901. DOI: 10.3390/nu16121801.


References
1.
Salas-Salvado J, Fernandez-Ballart J, Ros E, Martinez-Gonzalez M, Fito M, Estruch R . Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year results of the PREDIMED randomized trial. Arch Intern Med. 2008; 168(22):2449-2458. DOI: 10.1001/archinte.168.22.2449. View

2.
Trico D, Biancalana E, Solini A . Protein and amino acids in nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2020; 24(1):96-101. DOI: 10.1097/MCO.0000000000000706. View

3.
Corkey B . Banting lecture 2011: hyperinsulinemia: cause or consequence?. Diabetes. 2011; 61(1):4-13. PMC: 3237642. DOI: 10.2337/db11-1483. View

4.
Salas-Salvado J, Bullo M, Babio N, Martinez-Gonzalez M, Ibarrola-Jurado N, Basora J . Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care. 2010; 34(1):14-9. PMC: 3005482. DOI: 10.2337/dc10-1288. View

5.
Blanco-Rojo R, Alcala-Diaz J, Wopereis S, Perez-Martinez P, Quintana-Navarro G, Marin C . The insulin resistance phenotype (muscle or liver) interacts with the type of diet to determine changes in disposition index after 2 years of intervention: the CORDIOPREV-DIAB randomised clinical trial. Diabetologia. 2015; 59(1):67-76. DOI: 10.1007/s00125-015-3776-4. View